{"slug":"tesamorelin-glp-1","verification":{"valid":true,"entries":2,"head":"39474725bc59901f5ed48bdfaf0d44ebdff85ab2fbb0b1cafa185e9f8a9bb9fd"},"energy":{"passes":2,"tokens_in":43502,"tokens_out":4159,"tokens_total":47661,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"39474725bc59901f5ed48bdfaf0d44ebdff85ab2fbb0b1cafa185e9f8a9bb9fd"},"provenance":[{"ts":"2026-06-29T23:22:05.386Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Glp 1\nSlug: tesamorelin-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** GLP-1 agonists (class)\\n2. **What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs a","response":"{\n  \"slug\": \"tesamorelin-glp-1\",\n  \"title\": \"Tesamorelin and GLP-1 Agonists: Evidence on GH Axis, Visceral Fat, and Metabolic Pathways\",\n  \"body\": \"## What's breaking down\\n\\nNo single clinical condition is defined by the query. Readers often explore this pairing when GLP-1 agonists drive rapid weight loss. That process can shift body composition layers: overall fat drops, yet visceral adipose tissue around organs may persist or shift unevenly. Lean mass, including muscle, can decline during caloric deficit. The growth hormone axis may also blunt with age, illness, or metabolic stress, slowing tissue repair signals. Visceral fat accumulation links to lipid changes and liver fat in some populations. GLP-1 agonists primarily suppress appetite and slow gastric emptying to support weight reduction. This reduces mechanical load on joints and spine in proportion to lost body weight. Trade-offs include potential muscle loss if protein intake and resistance work lag. Tesamorelin enters discussion for its studied effect on the GH axis and selective visceral fat reduction.\\n\\n## Why Tesamorelin might help you\\n\\nTesamorelin acts as a growth hormone-releasing hormone analog. It binds pituitary receptors and raises endogenous growth hormone output in pulses, which elevates IGF-1. Higher GH signaling promotes lipolysis focused on visceral depots in studied groups. If visceral fat around organs forms part of the metabolic picture during or after GLP-1 use, this pathway targets that layer directly rather than overall scale weight. If lean mass preservation matters alongside fat loss, the same GH signal supports protein synthesis and muscle area in human data from HIV cohorts. The net effect discussed is repair-oriented: GH supports tissue maintenance instead of only suppressing caloric intake. Steps follow from mechanism: elevated GH increases lipolysis at visceral sites; IGF-1 rises correlate with fat redistribution in trials; lean body mass increases modestly without broad subcu","tokens_in":43502,"tokens_out":4159,"cost":0,"prev":"genesis","hash":"e61038d25174ddc344a239672587b8ba227761d03841439810a7db54336124e1"},{"ts":"2026-07-17T02:42:22.668Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-glp-1","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e61038d25174ddc344a239672587b8ba227761d03841439810a7db54336124e1","hash":"39474725bc59901f5ed48bdfaf0d44ebdff85ab2fbb0b1cafa185e9f8a9bb9fd"}]}